RELA and hepatocellular carcinoma: Given the performance of LDP in treating DN and reducing inflammation (15, 34), we empirically applied LDP in combination with apatinib to mice with HCC, and it was found that the combination significantly inhibited the activity of RelA and alleviated the proteinuria induced by apatinib alone.